Investors who take an interest in BioAtla, Inc. (NASDAQ:BCAB) should definitely note that the Co-Founder, Jay Short, recently paid US$2.14 per share to buy US$107k worth of the stock. While that's a very decent purchase to our minds, it was proportionally a bit modest, boosting their holding by just 2.3%.

Check out our latest analysis for BioAtla

The Last 12 Months Of Insider Transactions At BioAtla

In fact, the recent purchase by Jay Short was the biggest purchase of BioAtla shares made by an insider individual in the last twelve months, according to our records. So it's clear an insider wanted to buy, at around the current price, which is US$2.23. Of course they may have changed their mind. But this suggests they are optimistic. If someone buys shares at well below current prices, it's a good sign on balance, but keep in mind they may no longer see value. The good news for BioAtla share holders is that insiders were buying at near the current price.

While BioAtla insiders bought shares during the last year, they didn't sell. The chart below shows insider transactions (by companies and individuals) over the last year. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!

There are always plenty of stocks that insiders are buying. So if that suits your style you could check each stock one by one or you could take a look at this free list of companies. (Hint: insiders have been buying them).

Does BioAtla Boast High Insider Ownership?

I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. I reckon it's a good sign if insiders own a significant number of shares in the company. From our data, it seems that BioAtla insiders own 7.8% of the company, worth about US$8.3m. We do generally prefer see higher levels of insider ownership.

So What Do The BioAtla Insider Transactions Indicate?

It is good to see recent purchasing. And the longer term insider transactions also give us confidence. But on the other hand, the company made a loss during the last year, which makes us a little cautious. On this analysis the only slight negative we see is the fairly low (overall) insider ownership; their transactions suggest that they are quite positive on BioAtla stock. So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. Be aware that BioAtla is showing 4 warning signs in our investment analysis, and 3 of those make us uncomfortable...